Skip to main content

Table 5 Frequency of dizziness by study group adjusted by gender, age, anaemia at inclusion

From: Efficacy and tolerability of a new formulation of artesunate-mefloquine for the treatment of uncomplicated malaria in adult in Senegal: open randomized trial

Dizziness
Day 1   Day 2    Day 3  
  n (%) aOR** (95%CI) p value n (%) aOR (95%CI) p value n (%) aOR (95%CI) p value
*Treatment          
AL (n = 153) 17 (11.1%) 1   8 (5.2) 1   11 (7.1) 1  
AM (n = 157) 35 (22.3%) 2.2 (1.1-4.4) .02 61 (38.8) 12.5 (5.5 – 28.1) .001 58 (38.1) 10.2 (4.7-22.3) .001
  1. * AM = Artesunate-mefloquine; AL = Artemether-Lumefantrine.
  2. **aOR: adjusted odds ratio. The analysis of the association between dizziness and treatment was adjusted by mean haemoglobin at inclusion, age, gender.